First-ever targeted treatment for GPP recommended by NICE

As of today, 18th June 2025, Spesolimab (Spevigo) has been recommended by NICE as the first-ever targeted treatment for Generalised Pustular Psoriasis (GPP). GPP is rare form of psoriasis where pustules appear across large areas of the body.

Usual treatment for GPP includes biological treatments such as ciclosporin and acitretin. The treatment Spesolimab (Spevigo) can now be used to treat GPP flares in adults.

You can read the full NICE Guidance for Spesolimab in the link here.

About Spesolimab

Spesolimab, given as an intravenous infusion, is the first targeted and effective drug specifically developed for managing GPP flares.

It is estimated that just over 1,300 people with this condition in England could be set to benefit from this new treatment.

Get involved in our GPP everyday life survey

If you live in the UK, the Psoriasis Association would like to hear about your experiences of living with GPP.

You are invited to take part in a short anonymous online survey. Participants must be over the age of 18.

Your insights will help to shape vital research and support the GPP community.

The survey can be found here: https://www.surveymonkey.com/r/JRSMWQ6

If you require further information, please contact: research@psoriasis-association.org.uk.